Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYNK-001 in Multiple Myeloma Post-ASCT
NCT04309084Phase 1Unknown
- Sponsor
- Celularity Inc.
- Start
- May 2020
- Primary completion
- Jan 2023
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CYNK-001 in multiple myeloma (MM), sponsored by Celularity Inc. Primary endpoints: Dose-Limiting Toxicity up to 28 days, Maximum Tolerated Dose or Maximum Planned Dose up to 28 days and 2 more. Status: unknown.
02
Drugs
CYNK-001
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04309084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04309084.